DCLK2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL619295	1.00	2/20
SCHEMBL17721095	0.87	2/20
SCHEMBL17721077	0.87	2/20
SCHEMBL618577	0.87	2/20
SCHEMBL10098769	0.86	2/20
SCHEMBL10098768	0.84	2/20
SCHEMBL17721080	0.84	2/20
SCHEMBL617027	0.83	2/20
SCHEMBL10098761	0.78	2/20
SCHEMBL618312	0.78	2/20
SCHEMBL10098767	0.78	2/20
SCHEMBL10098807	0.77	2/20
SCHEMBL17465884	0.76	2/20
SCHEMBL16065702	0.75	2/20
SCHEMBL17721079	0.73	2/20
SCHEMBL617733	0.71	2/20
SCHEMBL10098752	0.71	2/20
SCHEMBL17721081	0.71	2/20
SCHEMBL619501	0.69	2/20
SCHEMBL619637	0.69	2/20

Clinical trials — most relevant to DCLK2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Acelarin First Line Randomised Pancreatic Study	PHASE2/PHASE3	SUSPENDED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Combined S-1 With DC+CIK As Maintenance Therapy For Advanced Pancreatic Ductal Adenocarcinoma	PHASE2/PHASE3	UNKNOWN
DC-CIK Immunotherapy Plus Chemotherapy vs Chemotherapy Alone in the Adjuvant Treatment of Stage III Colorectal Cancer	PHASE2/PHASE3	UNKNOWN
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy	PHASE2	COMPLETED
Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer	PHASE2	COMPLETED
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE)	PHASE1/PHASE2	NOT_YET_RECRUITING
DC Vaccine Combined With CIK Cells in Patients With SCLC	PHASE1/PHASE2	UNKNOWN
Valuation of the Safety and Efficacy of Combination of Cryoablation and Dendric Cell/Cytokine-induced Killers Cells Treatment for Advanced Liver Cancers	PHASE1/PHASE2	UNKNOWN
PKC412 and 5-Azacytidine	PHASE1/PHASE2	COMPLETED
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients	PHASE1/PHASE2	WITHDRAWN
Bryostatin 1 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer	PHASE2	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies	PHASE1	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Combination of Chemoradiation Therapy and Epitope Peptide Vaccine Therapy in Treating Patients With Esophageal Cancer	PHASE1	UNKNOWN
TSL2109 Capsules in Advanced Solid Tumor Patients: Safety, Tolerability, PK and Preliminary Efficacy	PHASE1	RECRUITING
A Study of PD1 Combined With Dc-cik in the Treatment of Solid Tumors	EARLY_PHASE1	UNKNOWN
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
DCLK1 as a Marker/Indicator of Stem Cell Response in Barrett's Esophagus/Esophageal Adenocarcinoma	nan	COMPLETED
RT201(Tumor Antigen-specific Macrophage Tumor Vaccine)	nan	UNKNOWN
Gene Expression Profiling of Malignant Tumor Predict the Therapeutic Response of DC-CIK Immunotherapy	nan	COMPLETED
Study of DC-CIK Combined With Chemotherapy for Advanced Solid Tumor	nan	UNKNOWN
Serum DCAMKL1 Pre and Post Treatment in Patients With Pancreatic Cancer	nan	ACTIVE_NOT_RECRUITING
Impact of Seasonal Malaria Chemoprevention on Immunity Against Malaria Among Children in Northern Benin	nan	COMPLETED
Safety and Efficacy of Immune Therapy for Condyloma	nan	UNKNOWN
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Rostock International Parkinson's Disease Study (ROPAD)	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a DCLK2 binder may also engage these)

Protein	Name	Similarity
Q6PGN3	—	1.000	Q6PGN3 →
Q5MPA9	—	1.000	Q5MPA9 →
D2I3C6	—	1.000	D2I3C6 →
DCLK1	Serine/threonine-protein kinase DCLK1	1.000	landscape →
Q9JLM8	—	0.999	Q9JLM8 →
B4NSS9	—	0.995	B4NSS9 →
Q7PLI7	—	0.994	Q7PLI7 →
B5DK35	—	0.992	B5DK35 →
B4IMC3	—	0.991	B4IMC3 →
B4IT27	—	0.991	B4IT27 →
O88809	—	0.991	O88809 →
DCX	Neuronal migration protein doublecortin	0.991	landscape →
G5EFD2	—	0.991	G5EFD2 →
Q8BX57	—	0.990	Q8BX57 →
O97143	—	0.990	O97143 →
O43150	—	0.990	O43150 →
Q9ESI7	—	0.990	Q9ESI7 →
B3NKK1	—	0.989	B3NKK1 →
B4GXC2	—	0.989	B4GXC2 →
P25799	—	0.989	P25799 →
Q66I46	—	0.989	Q66I46 →
KAT8	Histone acetyltransferase KAT8	0.989	landscape →
NFKB1	Nuclear factor NF-kappa-B p105 subunit	0.989	landscape →
P42159	—	0.989	P42159 →
D3ZA12	—	0.988	D3ZA12 →
Q2LYK3	—	0.988	Q2LYK3 →
Q19469	—	0.988	Q19469 →
Q04692	—	0.988	Q04692 →
Q9H1H9	—	0.988	Q9H1H9 →
Q19546	—	0.988	Q19546 →